BridgeBio Oncology Therapeutics, Inc.
BBOTNasdaq
$8.56
↑ +3.0%Jul 17 close · end-of-day
Price
1Y↓ -19.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$685,073.92
Enterprise Value
-$251.6M
P/E
—
P/S
—
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$154.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-41.4%
ROIC
-92.1%
Debt / Equity
—
Net Cash
$252.3M
Return 1Y
-20.0%
Company profile
We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.
- CEO
- Bihua Chen
- Sector
- Finance, Insurance, And Real Estate
- Industry
- Trading
- Headquarters
- Massachusetts
Management & directors
- Beltran PedroChief Scientific Officer
- Ben YongChief Med & Dev Officer
- Cobo MarcPrincipal Accounting Officer
- Elmelech IdanCOO & Principal Financial Ofcr
- Mehra UneekChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
BBOT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$526.11↑ +870.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$41,692.00 | -$80.9M | -$145.8M |
| Net income | -$41,692.00 | -$74.3M | -$134.0M |
| Diluted EPS | — | -$5,756.41 | -$4.30 |
| Operating cash flow | — | -$55.0M | -$113.9M |
| Free cash flow | — | -$55.1M | -$114.5M |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$152,343.00 | -$19.7M | -$21.9M | -$23.1M | -$1.1M | -$49.2M | -$43.4M | -$46.2M |
| Net income | -$21.8M | -$17.3M | -$19.7M | -$22.1M | -$28.4M | -$44.8M | -$38.8M | -$42.1M |
| Diluted EPS | — | -$1,562.18 | -$1,075.56 | -$54.23 | — | -$1.03 | -$0.49 | -$526.11 |
| Operating cash flow | -$29,099.00 | -$39.3M | -$15.0M | -$19.6M | $18.6M | -$70.6M | -$42.2M | -$35.9M |
| Free cash flow | — | — | — | -$19.8M | — | — | — | -$35.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 17, 2026
May 15, 2026
May 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Ben Yong· Chief Med & Dev Officer | Tax withholding | 1,047 | $7.80 | $8,166.60 | filing |
| 2026-07-01 | Beltran Pedro· President and CEO | Tax withholding | 1,047 | $7.80 | $8,166.60 | filing |
| 2026-07-01 | Elmelech Idan· COO & Principal Financial Ofcr | Tax withholding | 343 | $7.80 | $2,675.40 | filing |
| 2026-07-01 | Cobo Marc· Principal Accounting Officer | Tax withholding | 125 | $7.80 | $975.00 | filing |
| 2026-07-01 | Chen Bihua | J | 2,692,459 | $0.00 | $0.00 | filing |
| 2026-07-01 | Chen Bihua | J | 4,528,186 | $0.00 | $0.00 | filing |
| 2026-07-01 | Chen Bihua | J | 1,704,862 | $0.00 | $0.00 | filing |
| 2026-07-01 | Chen Bihua | J | 130,865 | $0.00 | $0.00 | filing |
| 2026-04-01 | Ben Yong· Chief Med & Dev Officer | Tax withholding | 1,047 | $9.03 | $9,454.41 | filing |
| 2026-04-01 | Beltran Pedro· President and CEO | Tax withholding | 1,047 | $9.03 | $9,454.41 | filing |
| 2026-04-01 | Mehra Uneek | Tax withholding | 524 | $9.03 | $4,731.72 | filing |
| 2026-03-10 | Ben Yong· Chief Med & Dev Officer | Award | 46,670 | $0.00 | $0.00 | filing |
| 2026-03-10 | Mehra Uneek· Chief Financial Officer | Award | 23,330 | $0.00 | $0.00 | filing |
| 2026-03-10 | Beltran Pedro· Chief Scientific Officer | Award | 46,670 | $0.00 | $0.00 | filing |
| 2025-10-10 | BridgeBio Pharma LLC | J | 784,720 | — | — | filing |
| 2025-08-11 | Chen Bihua | Award | 5,598,425 | $10.72 | $60.0M | filing |
| 2025-08-11 | Chen Bihua | Award | 760,496 | $10.72 | $8.2M | filing |
| 2025-08-11 | Chen Bihua | Award | 639,110 | $10.72 | $6.8M | filing |
| 2025-08-11 | Chen Bihua | D | 152,940 | $0.00 | $0.00 | filing |
| 2025-08-11 | Holman Albert A III | Option exercise | 30,000 | — | — | filing |
| 2025-08-11 | McKenna Mark C. | Option exercise | 30,000 | — | — | filing |
| 2025-08-11 | Schmid John P. | Option exercise | 30,000 | — | — | filing |
| 2025-08-11 | Chen Bihua | Option exercise | 4,172,126 | — | — | filing |
| 2025-08-11 | Chen Bihua | Award | 1,905,046 | — | — | filing |
| 2025-08-11 | Chen Bihua | Award | 1,762,760 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.